4/22/2021 8:14:03 AM
Eiger BioPharmaceuticals Appoints Veteran Kim Sablich To Board
2/23/2021 8:15:27 AM
Eiger : Primary And Secondary Endpoints Achieved In Phase 2 PREVENT Study Of Avexitide In Post-Bariatric Hypoglycemia
1/25/2021 8:17:25 AM
Eiger BioPharma Announces U.S. Commercial Availability Of Zokinvy
1/7/2021 8:14:38 AM
Eiger BioPharma : Phase 3 HDV D-LIVR Planned To Complete Enrollment In 2021
11/25/2020 8:51:01 AM
Eiger : FDA Oks Zokinvy To Treat Hutchinson-Gilford Progeria Syndrome And Processing-deficient Progeroid Laminopathies
11/23/2020 8:04:56 AM
Eiger BioPharma Sells Priority Review Voucher For $95 Mln
10/15/2020 8:25:52 AM
Eiger Announces Positive Results Of Investigator Sponsored Randomized Controlled Trial; Lambda Accelerated Viral Decline
9/28/2020 8:11:09 AM
Eiger Announces Results Of Study Of Peginterferon Lambda-1a In Outpatients With Mild And Uncomplicated COVID-19
8/31/2020 8:30:08 AM
Eiger Announces Peginterferon Lambda - Lonafarnib Combination End Of Treatment Results From Phase 2 LIFT HDV Study
4/30/2020 8:10:49 AM
Eiger BioPharma Unveils First COVID-19 Patient Dosed With Peginterferon Lambda
3/23/2020 8:22:44 AM
Eiger BioPharma Completes Submission Of NDA To FDA For Lonafarnib For Progeria And Progeroid Laminopathies
3/13/2020 8:01:46 AM
Eiger BioPharma Q4 Net Loss $16.9 Mln Or $0.69/Shr Vs Loss $16.5 Mln Or $0.93/Shr Last Year